Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413179 | 0.89 | KDM4E (0.65) | KDM4EALDH1A1EGLN2NOTUMEED | |
| Hydrochloric Acid SCHEMBL30411740 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1EGLN2NOTUMEED | |
| SCHEMBL30079590 | 0.80 | HTR3E (0.47) | NOTUMC5AR1 | |
| SCHEMBL28348705 | 0.78 | KDM4E (0.53) | KDM4EALDH1A1EGLN2NOTUMEED | |
| SCHEMBL23064539 | 0.77 | ALDH1A1 (0.48) | KDM4EALDH1A1GAAL3MBTL1CYP2A13 | |
| SCHEMBL14804180 | 0.74 | ALDH1A1 (0.41) | KDM4EALDH1A1EGLN2EEDFFAR4 | |
| Hydrochloric Acid SCHEMBL8729997 | 0.74 | KDM4E (0.55) | KDM4EALDH1A1EGLN2NOTUMGAA | |
| SCHEMBL27850036 | 0.74 | KDM4E (0.72) | KDM4EALDH1A1EGLN2NOTUMHPGD | |
| SCHEMBL2072485 | 0.73 | KDM4E (1.00) | KDM4EALDH1A1EGLN2EEDGAA | |
| SCHEMBL13125293 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | KDM4E 1499/4885ALDH1A1 2060/4885EGLN2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.